Sumitomo Pharma Co., Ltd.
4506
주식 순위
#3234
Sumitomo Pharma Co., Ltd. is a global company involved in the creation,... Sumitomo Pharma Co., Ltd. is a global company involved in the creation, production, and sale of a variety of products, including human pharmaceuticals, food ingredients and additives, and veterinary medicines. Its operations span across Japan, North America, China, and other international territories. The company's pharmaceutical offerings address a broad spectrum of medical needs. These include treatments for conditions such as Parkinson's disease, depression, type 2 diabetes, systemic fungal infections, hypertension, pruritus, chronic obstructive pulmonary disease (COPD), angina pectoris, and arrhythmia. Additionally, they manufacture atypical antipsychotics, antiepileptics, carbapenem antibiotics, gastrointestinal products, and specialized medications for Anderson-Fabry disease. Beyond healthcare, Sumitomo Pharma provides food components and enhancement agents like polysaccharides, along with savory flavorings such as soups and bouillons. The company also supplies chemical raw materials, which encompass pharmaceutical excipients, components for personal care products, substances used in coatings and industrial applications, and electronic materials. Moreover, it produces veterinary therapeutic solutions designed for domestic pets, specifically dogs and cats, as well as for various farm animals, including cattle, swine, poultry, horses, and cultivated fish. To drive innovation, Sumitomo Pharma fosters partnerships with several organizations. These collaborators include Healios K.K., Keio University, RIKEN, the Center for iPS Cell Research and Application, Kyoto University, and Aikomi Co., Ltd. The company also maintains a joint development agreement with SanBio Company Limited, a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd., and a strategic alliance with Roivant Sciences Ltd. Originally established in 1897, the company, headquartered in Osaka, Japan, was known as Sumitomo Dainippon Pharma Co., Ltd. until it adopted its current name, Sumitomo Pharma Co., Ltd., in April 2022. It functions as a subsidiary of Sumitomo Chemical Company, Limited.
주가
$12.28
시가총액
$5.51B
변동 (1일)
0.59%
변동 (1년)
8.21%
국가
JP
거래 Sumitomo Pharma Co., Ltd. (4506)
카테고리
Healthcare
Sumitomo Pharma Co., Ltd. (4506)의 수익
Jun 2026 기준 수익 TTM: $696.20M
Sumitomo Pharma Co., Ltd.의 최신 재무 보고서에 따르면 회사의 현재 수익은 $696.20M입니다. 2024년에 회사는 $-2.13B의 수익을 올렸으며 이는 2023년의 수익 $-360.91M과 감소입니다. 이 페이지에 표시된 수익은 이자 및 세금 공제 전 수익으로, 즉 EBIT입니다.
Sumitomo Pharma Co., Ltd.의 수익 기록 (2005 ~ 2026)
연말 수익
| 연도 | 수익 | 변화 |
|---|---|---|
| 2026 (TTM) | $696.20M | 492.57% |
| 2025 | $117.49M | -105.50% |
| 2024 | $-2.13B | 491.50% |
| 2023 | $-360.91M | -152.97% |
| 2022 | $681.35M | -3.06% |
| 2021 | $702.89M | -9.98% |
| 2020 | $780.81M | 33.24% |
| 2019 | $586.00M | -26.64% |
| 2018 | $798.75M | 88.42% |
| 2017 | $423.92M | 20.57% |
| 2016 | $351.60M | 24.93% |
| 2015 | $281.43M | -16.37% |
| 2014 | $336.52M | 74.64% |
| 2013 | $192.69M | -2.09% |
| 2012 | $196.80M | -34.88% |
| 2011 | $302.19M | -10.14% |
| 2010 | $336.28M | 2.87% |
| 2009 | $326.90M | -21.37% |
| 2008 | $415.75M | 27.67% |
| 2007 | $325.63M | 49.13% |
| 2006 | $218.36M | 100.02% |
| 2005 | $109.17M | 0.00% |
유사 기업 또는 경쟁사의 수익
| 회사 | 수익 | 수익 차이 | 국가 |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | 153.46% |
IN
|
